Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury

About this trial

This is a clinical trial to assess the safety, tolerability and pharmacokinetics (i.e. what the body does to a drug) of an experimental drug (MT-3921) in persons with spinal cord injury. If included, the participant will receive a single low dose of the MT-3921 drug injected into a vein. If the drug seems to be well tolerated, the participant will receive a high dose of the MT-3921 drug. Blood samples will be collected at 0, 1, 4, 8 hours, 1, 2, 7 days, and 1, 2, 3, 6 months after receiving the drug. This drug is an antibody treatment that has been shown in animal studies (e.g. mice and monkeys) to act against molecules that prevent guidance of regenerating nerve fibres.